Ninety-eight percent of Vanderbilt University Medical Center employees have received a flu vaccine in each of the past three years, according to data collected by the Vanderbilt Occupational Health Clinic, which oversees the employee flu vaccine program.

Using sophisticated gene sequencing and computing techniques, researchers at Vanderbilt University Medical Center and the San Diego Supercomputer Center have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2018.

Vanderbilt University Medical Center is participating in an international study to determine the effectiveness of a new therapeutic vaccine for treating women with precancerous changes on the cervix.

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

Internationally known vaccine experts including Vanderbilt University’s James Crowe Jr., MD, will speak next month at a symposium in Nashville on prospects for a universal flu vaccine.